Publication:
Baseline clinical characterization of participants in the Accelerating Medicines Partnership Schizophrenia Program

Simple item page
dc.contributor.authorAddington, Jean
dc.contributor.authorLiu, Lu
dc.contributor.authorChu, Monica
dc.contributor.authorJungert, Karl
dc.contributor.authorPenzel, Nora
dc.contributor.authorPasternak, Ofer
dc.contributor.authorFarina, Emily
dc.contributor.authorCarrion, Ricardo E.
dc.contributor.authorCorcoran, Cheryl M.
dc.contributor.authorMittal, Vijay A.
dc.contributor.authorStrauss, Gregory P.
dc.contributor.authorYung, Alison R.
dc.contributor.authorAlameda, Luis
dc.contributor.authorArango, Celso
dc.contributor.authorBorders, Owen
dc.contributor.authorBouix, Sylvain
dc.contributor.authorBreitborde, Nicholas J. K.
dc.contributor.authorBroome, Matthew R.
dc.contributor.authorCadenhead, Kristin S.
dc.contributor.authorCastillo-Passi, Rolando I.
dc.contributor.authorChen, Eric Yu Hai
dc.contributor.authorChoi, Jimmy
dc.contributor.authorColeman, Michael J.
dc.contributor.authorConus, Philippe
dc.contributor.authorDiaz-Caneja, Covadonga M.
dc.contributor.authorEllman, Lauren M.
dc.contributor.authorFusar Poli, Paolo
dc.contributor.authorGaspar, Pablo A.
dc.contributor.authorGerber, Carla
dc.contributor.authorGlenthøj, Louise Birkedal
dc.contributor.authorHorton, Leslie E.
dc.contributor.authorHui, Christy Lai Ming
dc.contributor.authorKambeitz, Joseph
dc.contributor.authorKambeitz-Ilankovic, Lana
dc.contributor.authorKapur, Tina
dc.contributor.authorKelly, Sinead
dc.contributor.authorKerr, Melissa J.
dc.contributor.authorKeshavan, Matcheri S.
dc.contributor.authorKim, Minah
dc.contributor.authorKim, Sung-Wan
dc.date.accessioned2026-07-23T13:06:02Z
dc.date.available2026-07-23T13:06:02Z
dc.date.issued2025
dc.descriptionNikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Kathryn E. Lewandowski, Daniel Mamah, Patricia J. Marcy, Daniel H. Mathalon, Catalina Mourgues, Merete Nordentoft, Angela R. Nunez, Godfrey D. Pearlson, Jesus Perez, Diana O. Perkins, Albert R. Powers III, Jack Rogers, Fred W. Sabb, Jason Schiffman, Johanna Seitz-Holland, Jai L. Shah, Steven M. Silversteinn, Stefan Smesny, William S. Stone, Judy L. Thompson, Rachel Upthegrove, Swapna Verma, Jijun Wang, Daniel H. Wolf, Tianhong Zhang, Lauren Addamo, Kate Buccilli, Dominic Dwyer, Sophie Todd, Youngsun T. Cho, Clara Fontenau, Zailyn Tamayo, Carrie E. Bearden, John M. Kane, Patrick D. McGorry, Rene S. Kahn, Martha E. Shenton, Scott W. Woods, Accelerating Medicines Partnership® Schizophrenia Barnaby Nelson, Monica E. Calkins
dc.description.abstractBackground. This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables and biomarkers in a total of 2040 clinical high-risk (CHR) participants and 652 community control (CC) participants. Methods. The dataset analyzed includes 1642 individuals at clinical high risk for psychosis and 519 CCs. Key measures include the Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the Structured Interview for Psychosis-Risk Syndromes, which determined CHR criteria and the severity of attenuated psychotic symptoms (APS). Other measures included the Structured Clinical Interview for DSM-5, scales to assess negative symptoms, depression, suicidal ideation, substance use, social and role functioning, and a selection of patient-reported outcomes. Results. CHR participants presented with more severe ratings on all clinical measures and poorer functioning relative to the CC. There were a few significant small associations between measures of APS and other clinical measures. Conclusion. The results from this study support previous research indicating that CHR individuals face serious clinical challenges beyond the risk of developing psychosis. Findings indicate significant associations among various clinical measures, underscoring the complex nature of the CHR population. Limitations are acknowledged, including the preliminary nature of the data and the need for more in-depth analyses from AMP SCZ papers already in progress. Future work will focus on longitudinal data and further exploration of clinical variables and their relationship with biomarkers.
dc.description.versionVersión publicada
dc.format.extent13 p.
dc.identifier.citationAddington, J., Liu, L., Chu, M., Jungert, K., Penzel, N., Pasternak, O., Farina, E., Carrion, R. E., Corcoran, C. M., Mittal, V. A., Strauss, G. P., Yung, A. R., Alameda, L., Arango, C., Borders, O., Bouix, S., Breitborde, N. J. K., Broome, M. R., Cadenhead, K. S., … Calkins, M. E. (2025). Baseline clinical characterization of participants in the Accelerating Medicines Partnership Schizophrenia Program. Schizophrenia Bulletin Open, 6(1), sgaf012. https://doi.org/10.1093/schizbullopen/sgaf012
dc.identifier.doihttps://doi.org/10.1093/schizbullopen/sgaf012
dc.identifier.urihttps://hdl.handle.net/11447/10901
dc.language.isoen
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.subjectClinical high risk
dc.subjectCommunity controls
dc.subjectPsychosis
dc.subjectAssessments
dc.subjectClinical outcomes
dc.subjectAMP SCZ
dc.titleBaseline clinical characterization of participants in the Accelerating Medicines Partnership Schizophrenia Program
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceSchizophrenia Bulletin Open
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Baseline clinical characterization of participants in the Accelerating Medicines Partnership Schizophrenia Program.pdf
Size:
1014.32 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Psicología

Implementado por OpenGeek Services